How to treat a signal? Current basis for RET-genotype-oriented choice of kinase inhibitors for the treatment of medullary thyroid cancer

Journal of Thyroid Research

Volumn 2011, Issue , 2011, Pages

  Prazeres, Hugo ^a,b,c   Torres, Joana ^a   Rodrigues, Fernando ^b   Couto, Joana P ^a,c   Vinagre, João ^a,c   Sobrinho Simões, Manuel ^a,c,d   Soares, Paula ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^c University of Porto   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AXITINIB; CABOZANTINIB; CARBAZOLE DERIVATIVE; CEP 2563; CEP 751; FORETINIB; GEFITINIB; INDOLE DERIVATIVE; LESTAURTINIB; MOTESANIB; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RPI 1; SEMAXANIB; SORAFENIB; SUNITINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB; ZALEPLON;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CLINICAL FEATURE; COMPLEX FORMATION; DIFFERENTIATED THYROID CANCER; DRUG CHOICE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE CLUSTER; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE RET; ONSET AGE; PENETRANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RADIATION EXPOSURE; REVIEW; SIPPLE SYNDROME; SOLID TUMOR; SOMATIC MUTATION; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT RESPONSE; TUMOR INVASION;

EID: 84862201270     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.4061/2011/678357     Document Type: Review

References (83)

1. M. Takahashi and G. M. Cooper, "ret Transforming gene encodes a fusion protein homologous to tyrosine kinases", Molecular and Cellular Biology, vol. 7, no. 4, pp. 1378-1385, 1987. (Pubitemid 17045226)
2. M. S. Airaksinen, A. Titievsky, and M. Saarma, "GDNF family neurotrophic factor signaling: four masters, one servant", Molecular and Cellular Neurosciences, vol. 13, no. 5, pp. 313-325, 1999. (Pubitemid 29256872)
3. T. Fukuda, K. Kiuchi, and M. Takahashi, "Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase", Journal of Biological Chemistry, vol. 277, no. 21, pp. 19114-19121, 2002. (Pubitemid 34952477)
4. A. Pandey, X. Liu, J. E. Dixon, P. P. Di Fiore, and V. M. Dixit, "Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7", Journal of Biological Chemistry, vol. 271, no. 18, pp. 10607-10610, 1996. (Pubitemid 26149895)
5. G. R. Panta, F. Nwariaku, and L. T. Kim, "RET signals through focal adhesion kinase in medullary thyroid cancer cells", Surgery, vol. 136, no. 6, pp. 1212-1217, 2004. (Pubitemid 39647536)
6. J. W. B. De Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra, "RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors", Endocrine Reviews, vol. 27, no. 5, pp. 535-560, 2006. (Pubitemid 44213230)
7. H. Murakami, T. Iwashita, N. Asai et al., "Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by Ret with the MEN 2B mutation", Biochemical and Biophysical Research Communications, vol. 262, no. 1, pp. 68-75, 1999. (Pubitemid 29412625)
8. C. Segouffin-Cariou and M. Billaud, "Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway", Journal of Biological Chemistry, vol. 275, no. 5, pp. 3568-3576, 2000. (Pubitemid 30083066)
9. M. Chiariello, R. Visconti, F. Carlomagno et al., "Signalling of the Ret receptor tyrosine kinase through the c-Jun. NH-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret", Oncogene, vol. 16, no. 19, pp. 2435-2445, 1998. (Pubitemid 28258576)
10. E. Arighi, M. G. Borrello, and H. Sariola, "RET tyrosine kinase signaling in development and cancer", Cytokine and Growth Factor Reviews, vol. 16, no. 4-5, pp. 441-467, 2005. (Pubitemid 41022013)
11. T. S. Gujral, W. Van Veelen, D. S. Richardson et al., "A novel RET kinase-β-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma", Cancer Research, vol. 68, no. 5, pp. 1338-1346, 2008. (Pubitemid 351346840)
12. M. Takahashi, J. Ritz, and G. M. Cooper, "Activation of a novel human transforming gene, ret, by DNA rearrangement", Cell, vol. 42, no. 2, pp. 581-588, 1985. (Pubitemid 16091150)
13. D. Hanahan and R. A. Weinberg, "The hallmarks of cancer", Cell, vol. 100, no. 1, pp. 57-70, 2000. (Pubitemid 30046295)
14. T. Watanabe, M. Ichihara, M. Hashimoto et al., "Characterization of gene expression induced by RET with MEN2A or MEN2B mutation", American Journal of Pathology, vol. 161, no. 1, pp. 249-256, 2002. (Pubitemid 34760790)
15. J. J. Schuringa, K. Wojtachnio, W. Hagens et al., "MEN2A-RET-induced cellular transformation by activation of STAT3", Oncogene, vol. 20, no. 38, pp. 5350-5358, 2001. (Pubitemid 32844066)
16. N. Asai, T. Fukuda, Z. Wu et al., "Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells", Development, vol. 133, no. 22, pp. 4507-4516, 2006. (Pubitemid 46017825)
17. G. W. McLean, N. O. Carragher, E. Avizienyte, J. Evans, V. G. Brunton, and M. C. Frame, "The role of focal-adhesion kinase in cancer-a new therapeutic opportunity", Nature Reviews Cancer, vol. 5, no. 7, pp. 505-515, 2005. (Pubitemid 40942827)
18. F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, "Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability", Carcinogenesis, vol. 30, no. 7, pp. 1073-1081, 2009.
19. M. G. Borrello, L. Alberti, A. Fischer et al., "Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene", Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 41, pp. 14825-14830, 2005. (Pubitemid 41457140)
20. N. Iwahashi, H. Murakami, Y. Nimura, and M. Takahashi, "Activation of RET tyrosine kinase regulates interleukin-8 production by multiple signaling pathways", Biochemical and Biophysical Research Communications, vol. 294, no. 3, pp. 642-649, 2002. (Pubitemid 34694059)
21. S. Shinohara and J. L. Rothstein, "Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells", Oncogene, vol. 23, no. 45, pp. 7571-7579, 2004. (Pubitemid 39389698)
22. V. Guarino, M. D. Castellone, E. Avilla, and R. M. Melillo, "Thyroid cancer and inflammation", Molecular and Cellular Endocrinology, vol. 321, no. 1, pp. 94-102, 2010.
23. E. Puxeddu, J. A. Knauf, M. A. Sartor et al., "RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response", Endocrine-Related Cancer, vol. 12, no. 2, pp. 319-334, 2005. (Pubitemid 40896450)
24. M. Muzza, D. Degl'Innocenti, C. Colombo et al., "The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies", Clinical Endocrinology, vol. 72, no. 5, pp. 702-708, 2010.
25. M. G. Borrello, D. Degl'Innocenti, and M. A. Pierotti, "Inflammation and cancer: the oncogene-driven connection", Cancer Letters, vol. 267, no. 2, pp. 262-270, 2008.
26. L. M. Mulligan, J. B. J. Kwok, C. S. Healey et al., "Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A", Nature, vol. 363, no. 6428, pp. 458-460, 1993. (Pubitemid 23179393)
27. H. Donis-Keller, S. Dou, D. Chi et al., "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC", Human Molecular Genetics, vol. 2, no. 7, pp. 851-856, 1993. (Pubitemid 23216611)
28. C. Eng, D. Clayton, I. Schuffenecker et al., "The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis", Journal of the American Medical Association, vol. 276, no. 19, pp. 1575-1579, 1996. (Pubitemid 26384740)
29. M. Santoro, F. Carlomagno, A. Romano et al., "Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B", Science, vol. 267, no. 5196, pp. 381-383, 1995.
30. M. D. Castellone, A. Verrienti, D. Magendra Rao et al., "A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization", Clinical Endocrinology, vol. 73, no. 4, pp. 529-534, 2010.
31. F. Lesueur, A. Cebrian, A. Cranston et al., "Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3454-3457, 2005. (Pubitemid 41014313)
32. P. Pigny, C. Bauters, J. L. Wemeau et al., "A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma", Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 5, pp. 1700-1704, 1999. (Pubitemid 30644279)
33. A. N. Cranston, C. Carniti, K. Oakhill et al., "RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B", Cancer Research, vol. 66, no. 20, pp. 10179-10187, 2006. (Pubitemid 44672073)
34. P. Soares, V. Trovisco, A. S. Rocha et al., "BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC", Oncogene, vol. 22, no. 29, pp. 4578-4580, 2003. (Pubitemid 36920701)
35. R. M. W. Hofstra, R. M. Landsvater, I. Ceccherini et al., "A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma", Nature, vol. 367, no. 6461, pp. 375-376, 1994.
36. O. Gimm, D. J. Marsh, S. D. Andrew et al., "Germline dinucleotide mutation in codon 883 of the RET protooncogene in multiple endocrine neoplasia type 2B without codon 918 mutation", Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 11, pp. 3902-3904, 1997. (Pubitemid 27509392)
37. A. Miyauchi, H. Futami, N. Hai et al., "Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation", Japanese Journal of Cancer Research, vol. 90, no. 1, pp. 1-5, 1999. (Pubitemid 29084304)
38. P. J. Morrison and N. C. Nevin, "Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome)", Journal of Medical Genetics, vol. 33, no. 9, pp. 779-782, 1996. (Pubitemid 26302493)
39. S. Bethanis, G. Koutsodontis, T. Palouka et al., "A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A", Hormones, vol. 6, no. 2, pp. 152-156, 2007.
40. I. Berndt, M. Reuter, B. Saller et al., "A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A", Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 3, pp. 770-774, 1998. (Pubitemid 28496443)
41. G. Pinna, G. Orgiana, A. Riola et al., "RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype", Thyroid, vol. 17, no. 2, pp. 101-104, 2007. (Pubitemid 46365563)
42. C. Jimenez, M. A. Habra, S. C. E. Huang et al., "Pheochromocytoma and medullary thyroid carcinoma: a new genotypephenotype correlation of the RET protooncogene 891 germline mutation", Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 4142-4145, 2004. (Pubitemid 39071525)
43. F. Raue and K. Frank-Raue, "Multiple endocrine neoplasia type 2:2007 update", Hormone Research, vol. 68, supplement 5, pp. 101-104, 2007.
44. R. T. Kloos, C. Eng, D. B. Evans et al., "Medullary thyroid cancer: management guidelines of the American Thyroid Association", Thyroid, vol. 19, no. 6, pp. 565-612, 2009.
45. S. Dvorakova, E. Vaclavikova, V. Sykorova et al., "Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas", Molecular and Cellular Endocrinology, vol. 284, no. 1-2, pp. 21-27, 2008.
46. M. M. Moura, B. M. Cavaco, A. E. Pinto et al., "Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas", British Journal of Cancer, vol. 100, no. 11, pp. 1777-1783, 2009.
47. X. Liu, Q. C. Vega, R. A. Decker, A. Pandey, C. A. Worby, and J. E. Dixon, "Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities", Journal of Biological Chemistry, vol. 271, no. 10, pp. 5309-5312, 1996. (Pubitemid 26083860)
48. D. Salvatore, R. M. Melillo, C. Monaco et al., "Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B", Cancer Research, vol. 61, no. 4, pp. 1426-1431, 2001. (Pubitemid 34292568)
49. I. P. Menacho, R. Koster, A. M. Van der Sloot et al., "RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor", Cancer Research, vol. 65, no. 5, pp. 1729-1737, 2005. (Pubitemid 40478598)
50. F. Carlomagno, D. Vitagliano, T. Guida et al., "The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes", Cancer Research, vol. 62, no. 4, pp. 1077-1082, 2002. (Pubitemid 34160290)
51. F. Carlomagno, D. Vitagliano, T. Guida et al., "ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases", Cancer Research, vol. 62, no. 24, pp. 7284-7290, 2002. (Pubitemid 36025251)
52. C. Lanzi, G. Cassinelli, T. Pensa et al., "Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative", International Journal of Cancer, vol. 85, no. 3, pp. 384-390, 2000. (Pubitemid 30030413)
53. D. W. Kim, Y. S. Jo, H. S. Jung et al., "An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 4070-4076, 2006. (Pubitemid 44536887)
54. S. J. Dawson, N. M. Conus, G. C. Toner et al., "Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma", Anti-Cancer Drugs, vol. 19, no. 5, pp. 547-552, 2008. (Pubitemid 351556406)
55. M. Croyle, N. Akeno, J. A. Knauf et al., "RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR", Cancer Research, vol. 68, no. 11, pp. 4183-4191, 2008.
56. N. A. Pennell, G. H. Daniels, R. I. Haddad et al., "A phase II study of gefitinib in patients with advanced thyroid cancer", Thyroid, vol. 18, no. 3, pp. 317-323, 2008. (Pubitemid 351415790)
57. F. Carlomagno, S. Anaganti, T. Guida et al., "BAY 43-9006 inhibition of oncogenic RET mutants", Journal of the National Cancer Institute, vol. 98, no. 5, pp. 326-334, 2006. (Pubitemid 43338212)
58. V. Gupta-Abramson, A. B. Troxel, A. Nellore et al., "Phase II trial of sorafenib in advanced thyroid cancer", Journal of Clinical Oncology, vol. 26, no. 29, pp. 4714-4719, 2008.
59. S. I. Sherman, L. J. Wirth, J. P. Droz et al., "Motesanib diphosphate in progressive differentiated thyroid cancer", New England Journal of Medicine, vol. 359, no. 1, pp. 31-42, 2008. (Pubitemid 351931094)
60. M. J. Schlumberger, R. Elisei, L. Bastholt et al., "Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer", Journal of Clinical Oncology, vol. 27, no. 23, pp. 3794-3801, 2009.
61. E. E. W. Cohen, L. S. Rosen, E. E. Vokes et al., "Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study", Journal of Clinical Oncology, vol. 26, no. 29, pp. 4708-4713, 2008.
62. J. P. Eder, L. Appleman, E. Heath et al., "A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs)", Journal of Clinical Oncology, vol. 24, no. 18S, p. 3041, 2006, ASCO Annual Meeting Proceedings Part I.
63. P. Lo Russo, L. Appleman, A. X. Zhu et al., "Pharmacodynamics of XL880, a novel spectrum selective kinase inhibitor (SSKI) administered orally in patients with advanced solid tumors (AST)", in Proceedings of the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, November 2006, Abstract 404.
64. R. W. Ross, M. Stein, J. Sarantopoulos et al., "A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC)", Journal of Clinical Oncology, vol. 25, no. 18S, p. 15601, 2007, ASCO Annual Meeting Proceedings.
65. R. Salgia, D. S. Hong, L. H. Camacho et al., "A phase I doseescalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies", Journal of Clinical Oncology, vol. 25, no. 18S, p. 14031, 2007, ASCO Annual Meeting Proceedings.
66. C. J. Strock, J. I. Park, M. Rosen et al., "CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth", Cancer Research, vol. 63, no. 17, pp. 5559-5563, 2003. (Pubitemid 37139878)
67. M. S. Cohen, H. B. Hussain, and J. F. Moley, "Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors", Surgery, vol. 132, no. 6, pp. 960-967, 2002. (Pubitemid 36026942)
68. M. A. Skinner, J. A. Moley, W. G. Dilley, K. Owzar, M. K. De Benedetti, and S. A. Wells, "Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A", New England Journal of Medicine, vol. 353, no. 11, pp. 1105-1113, 2005. (Pubitemid 41317433)
69. J. F. Lyons, S. Wilhelm, B. Hibner, and G. Bollag, "Discovery of a novel Raf kinase inhibitor", Endocrine-Related Cancer, vol. 8, no. 3, pp. 219-225, 2001. (Pubitemid 32947644)
70. Y. C. Henderson, S. H. Ann, Y. Kang, and G. L. Clayman, "Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement", Clinical Cancer Research, vol. 14, no. 15, pp. 4908-4914, 2008.
71. C. Lanzi, G. Cassinelli, G. Cuccuru et al., "Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1", Cellular and Molecular Life Sciences, vol. 60, no. 7, pp. 1449-1459, 2003. (Pubitemid 36900526)
72. D. B. Mendel, A. Douglas Laird, X. Xin et al., "In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship", Clinical Cancer Research, vol. 9, no. 1, pp. 327-337, 2003. (Pubitemid 36109749)
73. T. J. Abrams, L. B. Lee, L. J. Murray, N. K. Pryer, and J. M. Cherrington, "SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer", Molecular Cancer Therapeutics, vol. 2, no. 5, pp. 471-478, 2003.
74. C. J. Strock, J. I. Park, D. M. Rosen et al., "Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 79-84, 2006. (Pubitemid 43069121)
75. S. D. Undevia, N. J. Vogelzang, A. M. Mauer, L. Janisch, S. Mani, and M. J. Ratain, "Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors", Investigational New Drugs, vol. 22, no. 4, pp. 449-458, 2004. (Pubitemid 39619821)
76. T. K. Choueiri, "Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors", Current Opinion in Investigational Drugs, vol. 9, no. 6, pp. 658-671, 2008. (Pubitemid 351777169)
77. A. Polverino, A. Coxon, C. Starnes et al., "AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts", Cancer Research, vol. 66, no. 17, pp. 8715-8721, 2006. (Pubitemid 44449188)
78. F. Carlomagno, T. Guida, S. Anaganti et al., "Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors", Oncogene, vol. 23, no. 36, pp. 6056-6063, 2004. (Pubitemid 39178858)
79. P. P. Knowles, J. Murray-Rust, S. Kjær et al., "Structure and chemical inhibition of the RET tyrosine kinase domain", Journal of Biological Chemistry, vol. 281, no. 44, pp. 33577-33587, 2006. (Pubitemid 46036738)
80. I. Plaza-Menacho, L. Mologni, E. Sala et al., "Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting", Journal of Biological Chemistry, vol. 282, no. 40, pp. 29230-29240, 2007. (Pubitemid 350043334)
81. D. G. Pfister and J. A. Fagin, "Refractory thyroid cancer: a paradigm shift in treatment is not far off", Journal of Clinical Oncology, vol. 26, no. 29, pp. 4701-4704, 2008.
82. P. P. Joshi, M. V. Kulkarni, B. K. Yu et al., "Simultaneous downregulation of CDK inhibitors p18 and p27 is required for MEN2A-RET-mediated mitogenesis", Oncogene, vol. 26, no. 4, pp. 554-570, 2007. (Pubitemid 46160969)
83. W. Van Veelen, C. J. R. Van Gasteren, D. S. Acton et al., "Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development", Cancer Research, vol. 68, no. 5, pp. 1329-1337, 2008. (Pubitemid 351346839) Technology